Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
The Fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure.
Arch Intern Med, 153 (1993), pp. 154-183
[2.]
L. Tobian, H.R. Brunner, J. Cohn, H. Gavras, J.H. Laragh, B.J. Materson, et al.
Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V consensus guidelines.
Am J Hypertens, 7 (1994), pp. 859-872
[3.]
R.B. Devereux, M.H. Alderman.
Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events.
Circulation, 88 (1993), pp. 1444-1455
[4.]
P. Verdecchia, G. Schillaci, C. Borgioni, A. Ciucci, R. Gattobigio, I. Zampi, et al.
Prognostic significance of serial changes in left ventricular mass in essential hypertension.
Circulation, 97 (1998), pp. 48-54
[5.]
J.S. Yudkin, R.D. Forrest, C.A. Jackson.
Microalbuminuria as a predictor of vascular disease in non-diabetic subjects.
Lancet, 2 (1988), pp. 530-533
[6.]
Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med, 157 (1997), pp. 2413-2446
[7.]
Guidelines Sub-Committee.
1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension.
J Hypertens, 17 (1999), pp. 151-183
[8.]
J.L. Llisterri, G.C. Rodríguez, F.J. Alonso.
Antihipertensivos clásicos o modernos en el tratamiento de la hipertensión arterial: ¿debe seguir existiendo controversia en su elección?.
SEMERGEN, 28 (2002), pp. 560-572
[9.]
M.R. Weir, V.J. Dzau.
The renin-angiotensin-aldosterone system: a specific target for hypertension management.
Am J Hypertens, 12 (1999), pp. 205S-213S
[10.]
R.E. Schmieder, P. Martus, A. Klingbeil.
Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies.
JAMA, 275 (1996), pp. 1507-1513
[11.]
H.H. Parving.
Microalbuminuria in essential hypertension and diabetes mellitus.
J Hypertens, 14 (1996), pp. 89S-94S
[12.]
H.H. Parving, H. Lehnert, H. Brochner-Mortensen, R. Gomis, S. Anderson, P. Amer.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
N Engl J Med, 345 (2001), pp. 870-878
[13.]
E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, et al.
Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
N Engl J Med, 345 (2001), pp. 851-860
[14.]
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med, 342 (2000), pp. 145-153
Copyright © 2002. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
